1 published article · Updated continuously
12 trials tracked for Vaginal Atrophy: 9 in phase 3 or 4 and 6 with published results. The most-cited published study has 245 citations.
Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Estriol has been shown to significantly improve vaginal maturation values (MV) at both 3 weeks and 12 weeks of treatment compared to placebo 9. Additionally, estriol therapy is associated with a statistically significant reduction in vaginal pH over a 12-week period 10 and an increase in the proportion of superficial cells in the vaginal epithelium 10.
Placebo groups across multiple trials demonstrated varying baseline levels of parabasal and superficial cells, but consistent lack of improvement was noted compared to active interventions in specific metrics. For example, placebo groups showed a range of changes in parabasal cell percentages at 12 weeks [4, 5, 6, 8] and minimal changes in the percentage of superficial cells [4, 5, 6, 8].
While several trials evaluated different hormonal interventions including Estradiol [1, 3], Conjugated Estrogens 2, and DHEA 7, specific outcome data for these were not fully detailed in the provided evidence set beyond their inclusion in phase studies.
AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
